Lifestyle « Weekly Gravy

Being an Instagram influencer isn’t always a good thing. New research found that vulnerable young people who see online posts of self-harm — like cutting — may copy those destructive behaviors. Almost one-third of teens and young adults who reported seeing self-harm posts on Instagram said they had performed the same or similar self-harming behavior afterwards. Seeing these images online “normalizes” the behavior, according study senior author Dan Romer. He’s research director of the Annenberg Public Policy Center at the University of Pennsylvania. “Vulnerable kids think, ‘Well, maybe that’s something I should consider doing,’” he said. Romer noted that this problem goes beyond just Instagram. “Kids who don’t have mental health problems wouldn’t repeatedly self-harm. It’s vulnerable kids trying to relieve their distress,” he explained. But he added that this study indicates that these types of social media posts can be harmful to teens and young adults. The researchers initially became concerned about the potential effects of self-harm posts after a British father said his 14-year-old daughter had looked at explicit self-harming images on Instagram before killing herself. The social media site has since said that graphic depictions of self-harm aren’t allowed in posts. Self-harm typically refers to cutting, but can include other behaviors such as burning, hitting or head-banging. Self-harm isn’t usually suicidal, but people who engage in self-harm are at increased risk for… read on >

Whether it comes from demands at home, a slow commute or monthly bills, it’s hard to escape stress. Beyond affecting your mood, it can play havoc with your health, from lost sleep and stress-eating to weight gain and heart disease. Fortunately, you can take steps to counter all these negatives. A simple solution is a 20-minute daily break to practice relaxation in a tranquil spot away from annoyances. But when time is in short supply, you can still do a five-minute de-stress to refresh and refocus. Here are five effective ideas: Breathe with focus: Put all your concentration on taking long, deep breaths. Watch your belly expand as you inhale and contract as you exhale. Meditate: Build on focused breathing by silently repeating a mantra, which can be just a sound, one word or a short, life-affirming phrase of your choice. Exercise: Tap into the power of mood-boosting endorphins by spending a few minutes moving. You don’t even have to leave your office — just close the door and try walking or running in place at your desk. Or get the mind-body benefits of yoga with a simple move like the Tree Pose: Standing straight, bend your right knee out to the side to place the sole of your right foot against the inner thigh of your left leg. Hold for 30 to 60 seconds,… read on >

Adding a newer drug to standard hormone therapy lengthens the lives of younger women with advanced breast cancer, a new trial has found. The drug, called Kisqali (ribociclib), is already approved for treating such patients — based on earlier results showing it can delay the progression of their cancer. This is the first evidence it can also extend their lives, said senior researcher Dr. Debu Tripathy, chair of the breast medical oncology department at M.D. Anderson Cancer Center in Houston. After 3.5 years, 70% of patients given hormone therapy plus Kisqali were still alive. That compared with 46% of those given hormone therapy alone. That proof of a survival advantage hits “a pretty big milestone,” Tripathy said. And, he added, it argues for giving the drug as a “first-line or second-line” treatment to these patients. The findings were to be presented Tuesday at the American Society of Clinical Oncology annual meeting, in Chicago, and they will also be published in the New England Journal of Medicine. Kisqali is one of three newer drugs on the market called CDK4/6 inhibitors; the others are Verzenio (abemaciclib) and Ibrance (palbociclib). They work by blocking two proteins that help cancer cells grow and divide. Kisqali, taken as a tablet, was originally approved as a first-line treatment for postmenopausal women with advanced breast cancer that is hormone receptor-positive — which… read on >

Cutting-edge prostate cancer drugs that help extend life in the toughest cases might also be useful in fighting less aggressive tumors, two new clinical trials suggest. Two drugs that interfere with cancer’s ability to use testosterone for fuel, apalutamide (Erleada) and enzalutamide (Xtandi), are already approved for use against more advanced prostate tumors that don’t respond to regular therapy. But these trials show that the drugs also can improve survival and slow progression in prostate cancers that do respond to regular therapy, which typically involves medication that halts production of testosterone. Both clinical trials involved patients with prostate cancer that had spread to other parts of their body but who still responded to androgen-deprivation therapy. “We’re slowly starting to see a migration of drugs traditionally saved for advanced stages of disease, where we’re incorporating them into earlier stages of disease,” said Dr. Bobby Liaw, medical director of the Blavatnik Family Chelsea Medical Center at Mount Sinai, in New York City. He was not involved in the trials. Apalutamide combined with androgen-deprivation therapy caused a 33% reduction in overall risk of death, compared against patients who received a placebo alongside their androgen-deprivation therapy, said the lead researcher of that clinical trial, Dr. Kim Chi. Apalutamide also delayed progression of the cancer by 52%, and the length of time before patients required chemotherapy by 61%, said Chi,… read on >

More American women under age 65 have been diagnosed sooner and treated earlier for ovarian cancer since the Affordable Care Act went into effect in 2010, new research shows. And, more women received treatment within 30 days of diagnosis, improving their survival odds, the researchers said. For the study, the investigators analyzed data from the U.S. National Cancer Database. They compared nearly 36,000 women who were diagnosed and treated between 2004 and 2009, with more than 37,000 women diagnosed and treated between 2011 and 2014. Women in both groups were between 21 and 64 years of age. A similar number of seniors with ovarian cancer was used as a control group, because those women had access to Medicare and were much less likely to be uninsured before or after introduction of the Affordable Care Act, also known as Obamacare. Compared with the control group, there was a 1.7% gain in early-stage diagnosis and a 1.6% improvement in treatment within 30 days of diagnosis among younger women since 2010, the findings showed. The greatest gains were among women who got public insurance after the Affordable Care Act was introduced. These women had a 2.5% gain in early-stage diagnosis and timely treatment compared with the control group. The improvements were seen regardless of race, income or level of education. While a 1.7% improvement in early diagnosis may… read on >

Brittle bones are often seen as a woman’s health issue, but low bone mass may be more common among middle-aged men than generally thought, a small study suggests. The research, of 173 adults aged 35 to 50, found that men and women were equally likely to have low bone mass in the hip. It was found in 28% of men and 26% of women. Those study participants, the researchers said, had osteopenia, or lower-than-normal bone density. In some cases, it progresses to osteoporosis — the brittle-bone disease that makes people vulnerable to fractures. The fact that osteopenia was just as common in men came as a surprise, said researcher Allison Ford, a professor of health and exercise science at the University of Mississippi. Full-blown osteoporosis is clearly more common in women. About one-quarter of U.S. women aged 65 and up have the condition in the hip or lower spine, according to the U.S. Centers for Disease Control and Prevention. That compares with about 5% of men the same age. But, Ford said, the new findings suggest low bone density might be more common in middle-aged men than appreciated. “Low bone mineral density and osteoporosis affect men,” she said. “They should not be overlooked.” Ford suggested men take steps to help ensure their bones stay healthy — including eating a well-balanced diet with enough calcium, getting… read on >

Vaping is gaining a foothold in an unlikely population: New research shows a growing number of cancer patients are using electronic cigarettes. “The gradual but steady increase is quite striking,” said study author Dr. Nina Sanford, an assistant professor of radiation oncology at UT Southwestern Medical Center in Dallas. “The high prevalence of e-cigarette use among younger cancer patients and survivors is concerning.” E-cigarette use by cancer patients rose from 8.5% in 2014 to nearly 11% in 2017, according to the analysis of federal government data on more than 13,000 patients. Among patients younger than 50, the rate of use rose from 23% in 2014 to 27% in 2017. Use of conventional cigarettes by cancer patients remained stable between 2014 and 2017, according to Sanford. There is little known about e-cigarette use among cancer patients, she added. “Because e-cigarettes are relatively new, we don’t have the long-term data on their side effects yet,” Sanford said in a medical center news release. It’s known that conventional cigarettes can impair healing from surgery and radiation therapy, so it’s possible that e-cigarettes may cause similar problems, she noted. Sanford said patients often ask about e-cigarettes, and she advises them to avoid all kinds of smoking or vaping. “I don’t encourage it, but I also am honest that the jury is still out on what the long-term effects of… read on >